In April we learnt that the popular weight-loss drug Wegovy received approval in New Zealand. Developed by Novo Nordisk Pharmaceuticals, Wegovy (semiglutide) is a prescription medicine used to support weight loss and weight maintenance in addition to diet and physical activity. We now know that Wegovy will be available from the first week of July 2025.
Wegovy contains the active ingredient semiglutide. It belongs to a group of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 receptor agonists mimic a naturally occurring hormone to help regulate appetite and food intake.
GLP-1 receptor agonists mimic the hormone glucagon-like peptide-1 (GLP-1) which is produced by the gut and brain. Originally GLP-1 agonists were used to treat type 2 diabetes, but medicines like Wegovy were made specifically for weight loss and are approved as such.
Here are some of the ways GLP-1 agonists work:
For Adults
Wegovy is available as a prescription medicine used to support long-term weight management. It is meant to be used in adjunct (in addition) to a reduced-calorie diet and increased physical activity.
It may be suitable for adults who have a Body Mass Index (BMI) of
For Adolescents
Wegovy can be used in adjunct to a reduced-calorie diet and increased physical activity in young people aged 12 years or above with initial:
Wegovy should always be used under the guidance of a healthcare professional and as part of a wider plan that includes healthy eating and regular physical activity.
The most common side effects of Wegovy may include:
Tell your health care professional if you have any side effects that bother you.
